While it has been quite some time that the Biocon and Pfizer deal started making rounds on the bourses, but it is now quite evident that the dalal street has given a ok to the deal.

It is to be mentioned here that the share price of Biocon has recently touched a 52-week high on the markets in just the first four of trade in the markets. Bino Pathiparampil of IIFL said this is one of major developments that the company has had in this year and it is expected that it can open various opportunities for the country in the coming times as well.

He also mentioned that as the potential and the capability of the company has a lot of mettle it may even give more surprises to the investors in the coming times.

The stock has already performed very well on the bourses for the past three to four months as well but the recently touched high is one of the milestones for the company in this year.

The fact that a global pharma major has committed a huge sum of money in the deal; it is testifying the fact that Biocon has a great future going ahead.